TMCnet News

Symplmed and PuraCap Pharmaceutical LLC partner to distribute new EpiCeram-L™ Lip Care through DyrctAxess Technology
[October 01, 2015]

Symplmed and PuraCap Pharmaceutical LLC partner to distribute new EpiCeram-L™ Lip Care through DyrctAxess Technology


Symplmed announced today that it has entered into an agreement with PuraCap® Pharmaceutical LLC to distribute a new product, EpiCeram-L™ Lip Care, through Symplmed's patented DyrctAxess technology. The program is designed to provide physicians with easy access to PuraCap's growing portfolio of dermatology products.

From PuraCap Pharmaceutical LLC, the makers of EpiCeram® Controlled Release Skin Barrier Emulsion, comes a unique lip care formulation with an exclusive delivery system developed specifically for severely chapped, dry, or cracked lips. EpiCeram-L Lip Care uses patented MultiSal™ technology to deliver 3 essential lipids - ceramides, free fatty acids and cholesterol in an all-natural, fragrance-free, and color-free formulation. EpiCeram-L Lip Care is available exclusively through prescribing healthcare professionals.

"Partnering with PuraCap to accelerate their product distribution through our DyrctAxess platform is continued validation of our technology," said Erik Emerson (News - Alert), President and CEO of Symplmed Pharmaceuticals. "PuraCap has a strong, growing portfolio of dermatology products which we're excited to offer in their own customized execution of DyrctAxess."

"Symplmed demonstrated a strong understanding and history of success in the execution of direct ordering and fulfillment," said Elise Klein, Vice President and General Manager of PuraCap's Branded Rx division. "We look forward to working with Symplmed to continue to meet the needs of our physicians and patients through the introduction of EpiCeram-L Lip Care."

PuraCap is the third execution of Symplmed's DyrctAxess technology which is designed to streamline the product fulfillment process.

About Symplmed

Symplmed Pharmaceuticals is a private pharmaceutical company optimizing the value of its medicines and hose of its industry partners by streamlining the prescription process, from fulfillment and payment to therapeutic compliance and outcomes monitoring. The Company's patented technology platform, DyrctAxess™, enables direct delivery of medications to a patient's home and addresses the problem of unfilled prescriptions. Symplmed is taking a therapeutic area approach, ensuring that medications necessary to manage a particular disease state are available through its DyrctAxess platform. The Company's initial focus is high blood pressure (hypertension) with a proprietary ACE inhibitor ACEON® (perindopril erbumine) and Prestalia® a single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate. Symplmed also plans to expand its pipeline in multiple therapeutic areas. For more information, visit www.symplmed.com.



About PuraCap Pharmaceutical LLC

PuraCap Pharmaceutical LLC is an emerging, fully integrated pharmaceutical company with expertise in product development, manufacturing, and bringing affordable, world-class quality products to their customers. The PuraCap corporate structure supports a two-pronged approach for global growth with dedicated companies in the areas of prescription brands (PuraCap Pharmaceutical) as well as prescription generics and OTC and private label brands. PuraCap Pharmaceutical continues to innovate using our soft gel expertise and developing other soft gel options. Go to www.puracap.com for more information.


Forward-Looking Statement

All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Symplmed does business, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.


[ Back To TMCnet.com's Homepage ]